Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer

  • Authors:
    • Wanbin Li
    • Hongyan Zhang
    • Linqing Yang
    • Yunfei Wang
  • View Affiliations

  • Published online on: November 1, 2018     https://doi.org/10.3892/ol.2018.9653
  • Pages: 1211-1216
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer is the most aggressive type of gynecological cancer. The cause of the poor survival rate is the development of chemotherapy resistance to platinum‑based therapies, including cisplatin. The present study aimed to investigate the mechanism of cancerous inhibitor of protein phosphatase 2A (CIP2A)‑induced chemoresistance in ovarian cancer. The present study initially investigated the expression of CIP2A in the ovarian tumor tissue, cisplatin‑sensitive SKOV‑3 cell line, and cisplatin‑resistant ovarian carcinoma SKOV‑3CDDP/R cell line. In addition, CIP2A was knocked down using small interference RNA in ovarian cancer cells and the chemosensitivity of these cells was analyzed. The results demonstrated that CIP2A expression was significantly higher in patients with ovarian cancer and in the cisplatin‑resistant ovarian carcinoma SKOV‑3CDDP/R cell line at the mRNA and protein levels. The proliferation and chemosensitivity were decreased and enhanced, respectively, when CIP2A was knocked down. CIP2A silencing significantly promoted the apoptosis induced by cisplatin in SKOV‑3CDDP/R cells, suggesting that CIP2A participated in the cisplatin resistance of ovarian cancer cells and that CIP2A silencing enhanced the apoptosis induced by cisplatin. CIP2A may be considered as a potential candidate for modulating cisplatin therapy in ovarian cancer.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li W, Zhang H, Yang L and Wang Y: Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer. Oncol Lett 17: 1211-1216, 2019
APA
Li, W., Zhang, H., Yang, L., & Wang, Y. (2019). Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer. Oncology Letters, 17, 1211-1216. https://doi.org/10.3892/ol.2018.9653
MLA
Li, W., Zhang, H., Yang, L., Wang, Y."Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer". Oncology Letters 17.1 (2019): 1211-1216.
Chicago
Li, W., Zhang, H., Yang, L., Wang, Y."Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer". Oncology Letters 17, no. 1 (2019): 1211-1216. https://doi.org/10.3892/ol.2018.9653